REFERENCES
- Dekker G A, deVries J I, Doelitzsch P M, Huijgens P C, von Blomberg B M, Jakobs C, et al. Underlying disorders associated with severe early-onset pre-eclampsia. Am J Obstet Gynecol 1995; 173: 1042–8
- Bertina R M, Koeleman B P, Koster T, Rosendaal F R, Dirven R J, de Ronde H, et al. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7
- Nagy B, Tóth T, Rigó J, Jr, Karádi I, Romics L. Papp Z. Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. Clin Genet 1998; 53: 478–81
- Peek M J, Nelson-Piercy C, Manning R A, deSwiet M, Letsky E A. Activated protein C resistance in normal pregnancy. Br J Obstet Gynaecol 1997; 104: 1084–6
- Rotmensch S, Liberati M, Mittelmann M, Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol 1997; 177: 170–3
- Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 300: 517–22
- Dizon-Towson D S, Nelson L M, Easton K, Ward K. The Factor V Leiden mutation may predispose women to severe pre-eclampsia. Am J Obstet Gynecol 1996; 175: 902–5
- Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Hemost 1997; 77: 1052–4
- Rajkovic A, Catalano P M, Malinow M R. Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol 1997; 90: 168–71
- Frosst P, Blom H J, Milos R, Goyette P, Sheppard C A, Matthews R G, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–3
- Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997; 34: 525–6
- Kupferminc J M, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophylia in women with complications of pregnancy. N Engl J Med 1999; 340: 9–13
- Stankovics J, Melegh B, Nagy Á, Kis A, Molnár J, Losonczy H, et al. Frequency of Factor V G1691A (Leiden) mutation in Hungarian population [in Hungarian]. Orv Hetil 1998; 139: 1161–3
- Thorp A J, Zucker L M, Plapp V F, Rachel M J, Hinkle C. Factor V Leiden mutation and preeclampsia. J Matern Fetal Invest 1997; 7: 19–20
- Rai R S, Regan L, Chitoloie A, Donald J G, Cohen H. Placental thrombosis and second trimester miscarriage associated with activated protein C resistance. Br J Obstet Gynaecol 1996; 103: 842–4
- Aries F, Romero R, Joist H, Kraus F T. Thrombophilia: A mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern–Fetal Med 1998; 7: 277–86
- Brenner B, Lanir N, Thaler I. HELLP syndrome associated with Factor V R506Q mutation. Br J Haematol 1996; 92: 999–1001
- Seige M, Schweigart U, Moessmer G, Schneider K T, Classen M. Extensive hepatic infarction caused by thrombosis of right portal vein branches and arterial vasospasm in HELLP syndrome associated with homozygous Factor V Leiden. Am J Gastroenterol 1997; 93: 473–4
- Krauss T, Augustin H G, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and Factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998; 92: 457–60
- Grandone E, Margaglione M, Colaizzo D, Montanaro S, Pavone G, Di-Minno G. Prevalence of FV Leiden and MTHFR mutation in a patient with complicated pregnancies [Letter]. Thromb Haemost 1997; 77: 1036–7